secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001193125-23-228639
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon announces dual WEE1/PKMYT1 inhibitor ACR-2316; plans IND by Q4 2024
---------------------------------------------------------------------------

- ACR-2316 is a novel dual WEE1/PKMYT1 inhibitor designed using Acrivon’s AP3 precision proteomics platform.
- Preclinical studies show single-digit nM IC50 potency and potent single-agent anti-tumor activity in vitro and in vivo.
- IND-enabling studies underway; IND submission targeted for Q4 2024 to initiate monotherapy development.
- Updated corporate presentation confirms cash and marketable securities as of June 30, 2023, with cash runway into 2025.
- Company prioritizes ACR-2316 based on preclinical profile for OncoSignature-based patient selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/0001193125-23-228639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/d479176d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-228639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer